Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand

Stock Track

03/03

BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.

The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.

Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1139657449"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139657449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139657449?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139657449","market":"nz","top_or_hot":-1,"title":"Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand","media":"Stock Track","content":"<p>BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.</p><p>The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.</p><p>Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-03 22:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.</p><p>The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.</p><p>Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百濟神州","start_time":0,"source_url":"","article_id":"1139657449","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139657449","pubTimestamp":1772549849,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"个股追踪|品牌重塑后估值担忧BeOne Medicines盘中暴跌5.34%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}